Valproate sodium
Depacon (valproate sodium) is a small molecule pharmaceutical. Valproate sodium was first approved as Depacon on 1996-12-30. It is known to target histone deacetylase 1.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Valproate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DEPACON | AbbVie | N-020593 DISCN | 1996-12-30 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| valproate sodium | ANDA | 2022-11-01 |
| valproic acid | ANDA | 2023-03-30 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
312 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 5 | 5 | 22 | 30 | 7 | 68 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 7 | 2 | 3 | 7 | 9 | 27 |
| Healthy volunteers/patients | — | 17 | — | — | 3 | — | 20 | ||
| Schizophrenia | D012559 | EFO_0000692 | F20 | 2 | 1 | 2 | 5 | 2 | 12 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 3 | 3 | 1 | 1 | 7 |
| Dementia | D003704 | F03 | 1 | — | 2 | 2 | — | 5 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 1 | 1 | 2 | — | 5 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 3 | 1 | 1 | — | 5 |
| Glioma | D005910 | EFO_0000520 | 1 | 2 | — | 1 | — | 4 | |
| Mania | D000087122 | F30 | — | — | — | 4 | — | 4 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Seizures | D012640 | G40.4 | 1 | — | 3 | — | 2 | 6 | |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | 5 | — | — | 6 |
| Glioblastoma | D005909 | EFO_0000515 | 2 | 2 | 1 | — | — | 5 | |
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | 2 | 1 | — | 2 | 5 |
| Spinal muscular atrophy | D009134 | EFO_0008525 | G12.1 | 1 | 2 | 1 | — | — | 4 |
| Astrocytoma | D001254 | EFO_0000271 | 1 | 1 | 1 | — | — | 3 | |
| Diffuse intrinsic pontine glioma | D000080443 | — | 1 | 1 | — | — | 2 | ||
| Neuroepithelial neoplasms | D018302 | — | 1 | 1 | — | — | 2 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | 1 | — | — | 2 |
| Uterine cervical neoplasms | D002583 | — | 1 | 1 | — | — | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 13 | 2 | — | — | — | 14 | |
| Myelodysplastic syndromes | D009190 | D46 | 2 | 8 | — | — | — | 9 | |
| Myeloid leukemia acute | D015470 | C92.0 | 4 | 8 | — | — | — | 9 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 3 | 2 | — | — | 1 | 5 | |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 3 | — | — | — | 5 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 3 | 1 | — | — | — | 4 |
| Leukemia | D007938 | C95 | 1 | 3 | — | — | — | 3 | |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | 2 | — | — | 1 | 3 |
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | 1 | — | — | — | 2 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 2 | 1 | — | — | — | 2 |
Show 40 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | 3 | — | — | — | 1 | 4 | ||
| Drug interactions | D004347 | 3 | — | — | — | — | 3 | ||
| Nasopharyngeal neoplasms | D009303 | 2 | — | — | — | — | 2 | ||
| Central nervous system neoplasms | D016543 | 2 | — | — | — | — | 2 | ||
| Traumatic brain injuries | D000070642 | S06 | 1 | — | — | — | 1 | 2 | |
| Hemorrhagic shock | D012771 | 2 | — | — | — | — | 2 | ||
| Mantle-cell lymphoma | D020522 | C83.1 | 1 | — | — | — | — | 1 | |
| Burkitt lymphoma | D002051 | C83.7 | 1 | — | — | — | — | 1 | |
| Non-small-cell lung carcinoma | D002289 | 1 | — | — | — | — | 1 | ||
| Urologic neoplasms | D014571 | C64-C68 | 1 | — | — | — | — | 1 |
Show 20 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
| Metabolic bone diseases | D001851 | HP_0000938 | — | — | — | — | 1 | 1 | |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
| Body composition | D001823 | — | — | — | — | 1 | 1 | ||
| Alveolar bone loss | D016301 | — | — | — | — | 1 | 1 | ||
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
| Nocturnal enuresis | D053206 | N39.44 | — | — | — | — | 1 | 1 | |
| Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | — | — | — | 1 | 1 |
| Cluster headache | D003027 | HP_0012199 | G44.00 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VALPROATE SODIUM |
| INN | valproic acid |
| Description | Valproic acid is a branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem. It has a role as an anticonvulsant, a GABA agent, an EC 3.5.1.98 (histone deacetylase) inhibitor, a teratogenic agent, a psychotropic drug, a neuroprotective agent and an antimanic drug. It is a branched-chain saturated fatty acid and a branched-chain fatty acid. It is functionally related to a valeric acid. It is a conjugate acid of a valproate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCC(CCC)C(=O)[O-].[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 99-66-1 |
| RxCUI | 11118 |
| ChEMBL ID | CHEMBL433 |
| ChEBI ID | 9925 |
| PubChem CID | 3121 |
| DrugBank | DBSALT001257 |
| UNII ID | 614OI1Z5WI (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HDAC1
HDAC1
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 48,295 documents
View more details
Safety
Black-box Warning
Black-box warning for: Valproate sodium, Valproic acid
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more